Tarlatamab for Treatment of Small Cell Lung Cancer in Clinical Practice: A Multicenter U.S. Retrospective Cohort Study from the ONWARD consortium.
Abstract
Background
Real-world data on efficacy and safety of tarlatamab in small cell lung cancer (SCLC) remains limited.
Methods
This retrospective study analyzed 265 tarlatamab-treated patients across 11 U.S. centers in the ONWARD-SCLC consortium (11/2023-4/2025), evaluating clinical outcomes, CRS, ICANS, and impact of prophylactic medications.
Results
Median age was 66 years; 87.2% had ECOG 0-1, 90.6% had de novo SCLC, and 44.5% and 39.2% had new/progressive brain and liver metastases before tarlatamab, respectively. Median prior lines of therapy were 2 (range 0-6). At a median follow-up of 4.9 months, DCR was 52.6% for evaluable SCLC cohort (all-treated: 37.9%). Median rw-PFS and rw-OS were 2.3 and 8.0 months. Median rw-PFS was 2.2 months among patients without brain metastasis versus 2.3 months among those with pre-existing brain metastasis (p=0.542). Following Cycle 1 Day 1 (C1D1), CRS occurred in 40.8% (Grade 3-4: 3.8%) and ICANS in 21.5% (Grade 3-4: 6%), with incidence declining markedly on subsequent doses. Compared to no-prophylaxis (N=237), prophylactic tocilizumab (N=19) was associated with lower CRS (5.3% vs. 43.0%; adj. p=0.017), ICANS (0% vs 22.4%; adj. p=0.041), and "prolonged hospitalization" rate (21.1% vs. 54.9%; adj. p=0.023). Multivariable analysis identified insulin-dependent diabetes, liver metastases, number of prior treatments, recent urgent care admissions, and low albumin/elevated ALT as independent predictors of worse OS.
Conclusion
Tarlatamab demonstrated meaningful clinical activity in pretreated real-world cohort, including those with brain metastases. Grade ≥3 CRS and overall/grade ≥3 ICANS incidence in C1 were higher than in clinical trials. Prophylaxis patterns were characterized and warrant prospective validation.